Ruxolitinib Safety in Steroid-Refractory Chronic GVHD
A brief overview of safety and adverse events in the REACH3 trial of ruxolitinib in patients with steroid-refractory chronic GVHD.
EP: 1.Overview: A 42-Year-Old Woman With Moderate Steroid-Refractory Chronic GVHD
EP: 2.Risk Factors for Chronic GVHD and Steroid-Refractory Disease
EP: 3.Symptoms and Manifestations of Chronic GVHD
EP: 4.Early Diagnosis of Chronic GVHD and Tools for Severity Assessment
EP: 5.Treatment Options for Steroid-Refractory Chronic GVHD
EP: 6.Ruxolitinib Efficacy in Steroid-Refractory Chronic GVHD
EP: 7.Ruxolitinib Safety in Steroid-Refractory Chronic GVHD
EP: 8.Reflections on the Case and Risk Management for Chronic GVHD
EP: 9.Steroid-Refractory Chronic GVHD: Unmet Needs and Future Directions
Case: A 42-Year-Old Woman With Moderate Steroid-Refractory Chronic Graft-Versus-Host Disease
Initial Presentation
- A 42-year-old woman previously underwent myeloablative conditioning and an allogeneic PBSC transplant for acute myeloid leukemia
- Received tacrolimus and methotrexate for GVHD prophylaxis
- At 11 months post-transplant, patient developed moderately dry and painful eyes, mild muscle and joint pain, mild erythematous rash on face and arms
First-line Treatment
- Patient received eye drops, topical steroid cream for rash, and was started on oral prednisone at 0.5 mg/kg/day
- After 4 weeks of treatment, eye dryness resolved, but the patient’s skin rash and muscle/joint pain worsened; steroid dose was increased to 1 mg/kg/day
- Skin rash and muscle/joint pain continued despite increased steroid dose
Second-line Treatment
Patient is now receiving ruxolitinib 10 mg orally twice daily, alongside 1 mg/kg/day steroids
Pacritinib, Sirolimus, and Tacrolimus Combo Fails to Improve GVHD Outcomes
August 10th 2024A phase 2 study found that a combination of pacritinib, sirolimus, and tacrolimus successfully suppressed pSTAT3 and Th1/Th17 cells, but failed to prevent acute graft-versus-host disease following allogeneic transplant.
Read More
Buprenorphine as an Alternative for Pain Management in Bone Marrow Transplants
August 1st 2024Mayuko Sakae, MD, discussed research on pain management for patients undergoing bone marrow transplants, highlighting the potential buprenorphine shows in offering a valuable alternative to traditional opioids.
Read More
BLA for Remestemcel-L to Treat Pediatric SR-aGVHD Resubmitted to FDA
July 10th 2024The application of remestemcel-L, a potential first-of-its-kind treatment for pediatric patients following stem cell transplants, has been resubmitted for FDA approval after addressing previous concerns.
Read More
